AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) granted EUSA Pharma the exclusive European rights to tivozanib to treat advanced renal cell carcinoma. The stock price climbed 23 cents to close at $1.26.
AVEO Pharmaceuticals grants tivozanib rights
December 21, 2015 at 15:52 PM EST
